MODIPAFANT

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H29ClN6O3
Molecular Weight	605.085
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C1=C(NC(C)=C([C@H]1C2=CC=CC=C2Cl)C(=O)NC3=NC=CC=C3)C4=CC=C(C=C4)N5C(C)=NC6=CN=CC=C56

InChI

InChIKey=ODRYSCQFUGFOSU-SSEXGKCCSA-N

InChI=1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)/t30-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7735582 | https://www.ncbi.nlm.nih.gov/pubmed/8025768 | https://www.ncbi.nlm.nih.gov/pubmed/8420437

Modipafant is a dihydropyridine derivative patented by American multinational pharmaceutical corporation Pfizer Ltd. as platelet-activating factor antagonist for bronchoconstriction and asthma treatment. Platelet-activating factor, proposed as an important inflammatory mediator in asthma, reproduces several of the features of asthma, such as microvascular leakage, mucus secretion, bronchoconstriction, and possibly increased airway responsiveness. Unfortunately, in clinical trials, Modipafant failed to demonstrate superior efficacy compared to placebo.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma.	1995-05	7735582

Patents

Sample Use Guides

In Vivo Use Guide

50 mg capsule twice daily

Route of Administration: Oral

Name

Type

Language

UK-80067

Preferred Name

English

MODIPAFANT

Official Name

English

ETHYL (+)-(R)-4-(O-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-2-(P-(2-METHYL-1H-IMIDAZO(4,5-C)PYRIDIN-1-YL)PHENYL)-5-(2-PYRIDYLCARBAMOYL)NICOTINATE

Common Name

English

modipafant [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327